REDEYE FIGHT CANCER DAY

JANUARY 19, 2023

JENS LINDBERG, CEO MEDIVIR AB

MEDIVIR

Important notice

You must read the following before continuing. The following applies to this document and the information provided in this presentation by Medivir AB (publ) (the "Company") or any person on behalf of the Company and any other material distributed or statements made in connection with such presentation (the "Information"), and you are therefore advised to carefully read the statements below before reading, accessing or making any other use of the Information. In accessing the Information, you agree to be bound by the following terms and conditions.

The Information does not constitute or form part of, and should not be construed as, an offer of invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or a successor entity or any existing or future subsidiary or affiliate of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any of such subsidiaries or affiliates nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Specifically, this presentation does not constitute a "prospectus" within the meaning of the U.S. Securities Act of 1933, as amended.


The Information may not be reproduced, redistributed, published or passed on to any other person, directly or in directly, in whole or in part, for any purpose. The Information is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The Information is not for publication, release or distribution in the United States, Australia, Canada or Japan, or any other jurisdiction in which the distribution or release would be unlawful.

All of the Information herein has been prepared by the Company solely for use in this presentation. The Information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained herein. The Information contained in this presentation should be considered in the context of the circumstances prevailing at that time and will not be updated to reflect material developments which may occur after the date of the presentation. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes.

This presentation may contain certain forward-looking statements and forecasts which relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on the Company's operations, financial position and earnings. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realized. Factors that could cause these differences include, but are not limited to, implementation of the Company's strategy and its ability to further grow, risks associated with the development and/or approval of the Company's potential market and industry, the ability to develop new products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. While the Company always intends to express its best judgment when making statements are not a guarantee of its performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances. Many of these risks are outside of the Company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically decline, any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments.



Medivir - A Swedish biotech focused on development of innovative treatments for cancer





Focused strategy with clear priority for first-in-class, orphan drug in liver cancer

Active partnering strategy for additional value creation across product portfolio



Fostroxacitabine bralpamide (fostrox)



Fostrox – A unique, first-in-class potential treatment for primary liver cancer



Significant unmet need & commercial potential with HCC market estimated to grow 5-fold in 10 years from \$1 - 5bn




Unique MoA that selectively targets cancer in the liver and bypasses resistance mechanisms

\mathbf{A}	
X	

Strong potential for attractive combinations with both existing classes of drugs in liver cancer



Fostrox – Combination of pro-drug technology & chemotherapy to minimise systemic side effects




Ŵ




Fostrox – inducing DNA damage & cell death in HCC tumour cells, sparing normal liver tissue


Significantly higher proliferation rate in liver tumour cells vs normal liver cells¹, indicating vulnerability to chemotherapy

Ki67 (biopsyonly)



DNA-damage & cell death observed with Fostrox in tumor tissue but not in normal liver tissue²








Clinical data indicating efficacy as monotherapy despite heavily pre-treated patient cohort



Encouraging changes in liver target lesions for HCC patients with 4 out of 7 reaching Stable Disease¹




Heavily pre-treated patient cohort predicting limited clinical benefit

- Treatment-refractory HCC, including fibrolamellar HCC, iCCA, or metastatic liver disease with limited extrahepatic tumour burden were recruited to phase 1 monotherapy study
- Patients had on average 2.8 years since diagnosis and on average >2 lines of previous therapy



HCC is a significantly growing market with large unmet need

HCC market estimated to grow almost five-fold until 2029



Despite recent advancements, unmet need is still high


- Liver cancer incidence and mortality are increasing with liver cancer the third leading course of cancer death worldwide 3%^{1,2}
- Despite recent advances in treatment of HCC, still only ~1/3 of patients respond to the best approved combination therapies
- <u>The HCC market growth is driven by combination</u> <u>therapies and patients treated in earlier disease stages</u>

Source: GlobalData 2021

MEDIVIR



Current pipeline of new HCC therapies consists of a variation of combination trials with two key mechanisms of actions








Fostrox – A unique, differentiated mechanism in HCC inhibiting DNA replication; strong potential for combinations

Fostrox + stimulation of immune system (PD-1)

Fostrox + blocking blood supply to tumor (TKI)




"Fostrox induces DNA damage and tumor cell death, potentially leading to **increased tumor antigen presentation and increased immune response**" "TKI's induce lack of oxygen in tumors leading to increased PGK1* expression and most importantly **higher levels of fostrox active metabolite**"



Ongoing phase 1b/2a combination study in 2nd line HCC exploring combinations with both anti-PD-1 & TKI

Ŵ





Strategic evolution & vision for fostroxacitabine bralpamide in liver cancer

Fostrox; Go-To option for combinations across liver related tumours

Advanced HCC

Launch as preferred combination partner in select patient group(s) in advanced HCC with TKI and/or PD-1

Backbone in HCC

Establish as backbone for combinations across HCC with potential for triple combinations & earlier lines

Beyond HCC

Explore potential in other liver related tumors beyond HCC such as CRC driven liver metastasis



Portfolio of partnering projects



15571

Partnering projects progressing during 2022

PROJECT	PARTNER	DISEASE AREA	PRE- CLINICAL	PH 1	PH 2	PH 3	ON MARKET	FINANCIALS	KEY EVENTS DURING 2022
Xerclear	GSK, SYB	Herpes						Royalties	
Remetinostat	TBD	CTCL, BCC, SCC						TBD	
MIV-711	TBD	Osteoarthirtis						TBD	
Birinapant	IGM Biosciences	Solid tumors						Milestones (up to \$350m) & royalties	 Cleared 3 out of 4 dose cohorts
USP-1	Tango Therapeutics	Cancer						Milestones & royalties	 CD selected, opening IND in 2023
USP-7	Ubiquigent Limited	Cancer						Revenue share	
MBLI	INFEX Therapeutics	Infection						Revenue share	FDA QIDP designationMoving to clinic in 2023



Thank You!

0

•

`